Immunotherapies have revolutionized the treatment landscape for metastatic melanoma over the past decade. Checkpoint inhibitors like ipilimumab, nivolumab, and pembrolizumab work by removing the brakes on the immune system allowing T cells to recognize and attack cancer cells. Ipilimumab was the first FDA-approved immunotherapy for metastatic melanoma in 2011. It works by targeting CTLA-4, a...
English
Arabic
Français
Español
Português
Türkçe
Dutch
Italiano
Russian
Romaian